You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: Anika Therapeutics Announces Decision to Proceed with CINGAL Premarket Review Through FDA's Center for ... FirstWord Pharma, 2 months ago
3 images for "fda centre for drug evaluation and research"
The US Food and Drug Administration (FDA) has approved Merck's Zepatier (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection, with or without ribavirin (RBV). Zepatier ...European Pharmaceutical Review, 2 weeks ago FDA approves Eisai's Halaven in liposarcoma European Pharmaceutical Review, 2 weeks ago FDA approves Allergan's Botox to treat lower limb spasticity in adults Pharmaceutical Technology, 2 weeks ago FDA approves Basaglar, a long-acting insulin treatment European Pharmaceutical Review, 1 month ago
A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai Sun Pharmaceutical Industry's fortunes on the bourses continue to remain topsy-turvy. Just as the stock was gaining some ...Business Standard India, 1 month ago
FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)
- The panel voted 8-2 that substantial evidence has been presented to support a claim of effectiveness for Brintellix for treating certain aspects of cognitive dysfunction in MDD- The panel discussed that cognitive dysfunction in MDD represents an ...TickerTech.com, 1 week ago
MADISON, Wis., and CASTRES, France, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Pierre Fabre, the third largest French pharmaceutical company, and Cellectar Biosciences, Inc. ( NASDAQ:CLRB ), an oncology-focused biotechnology company, today announce a ...Market Pulse Navigator, 1 month ago Cellectar Biosciences : and Pierre Fabre Laboratories Announce Oncology Research Collaboration 4 Traders, 1 month ago
Researchers at Cardiff University developed a method for improving the delivery of therapeutic molecules to kill cancer cells and cells affected by other diseases, such as tuberculosis. Due to their inability to reach the targeted parts of an ...Drug Development Technology, 1 month ago
The FDA has approved alectinib (Alecensa, Genentech) to treat patients with advanced (metastatic) anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate, treatment ...Advance for Nurses, 1 month ago FDA approves Roche's Alecensa for ALK-positive NSCLC European Pharmaceutical Review, 2 months ago
Does the U.S. Food and Drug Administration control the price of drugs? Do other countries approve drugs faster than the United States? Can the FDA tell doctors how to prescribe drugs? There is a lot of misinformation about exactly what the FDA does ...PM 360, 1 month ago FDA approves AstraZeneca's gout drug Zurampic Pharmafile, 1 month ago FDA approves Zurampic for patients with gout European Pharmaceutical Review, 1 month ago
The US Food and Drug Administration (FDA) has approved Actelion's Uptravi (selexipag) for the treatment of pulmonary arterial hypertension. Uptravi belongs to a class of drugs called oral IP prostacyclin receptor agonists. The drug acts by relaxing ...European Pharmaceutical Review, 1 month ago The New England Journal of Medicine publishes "Selexipag for the treatment of pulmonary arterial hypertension" EuroInvestor, 1 month ago GNW-News: The New England Journal of Medicine publishes "Selexipag for the treatment of pulmonary arterial hypertension" (english) Pharmacy Choice, 1 month ago
Researchers evaluated the content of 51 e-cigarettes, specifically focusing on flavors that would be appealing to children and adolescents. Since the introduction of e-cigarettes in 2004, their use has grown dramatically, with a number of ...AlterNet.org, 1 month ago
on your WebpageAdd Widget >Get your members hooked!